DiaSorin is a high-margin specialty diagnostics compounder temporarily pressured by China, FX, and respiratory seasonality, but its recurring reagent model, moated installed base, and new molecular platforms create attractive long-term upside.
Overview
DiaSorin is a global specialty diagnostics leader with a recurring razor-and-blade model: proprietary instruments create long-term reagent consumption, with consumables representing roughly 85%–90% of revenue. The company focuses on high-value specialty assays rather than commoditized core lab testing, with leadership in Vitamin D, infectious disease, endocrinology, molecular diagnostics, and licensed technologies. The Luminex acquisition shifted the business toward North America and added xMAP multiplexing capabilities. Its durable installed base, specialty menu, and high switching costs support resilient margins despite near-term FX, China, and respiratory-season headwinds.